pocketful logo light
pocketful logo light
Godavari Drugs Ltd logo

Godavari Drugs Ltd

NSE: BSE: 530317

₹101

(1%)

Tue, 25 Aug 2026, 09:00 pm

Godavari Drugs Share Price Live Chart

1 Day

(1%)

No Result Found

Summary

  • Market Cap (in Cr)

    128.72

  • Net Profit (in Cr)

    4.38

  • P/B

    1.52

  • Sector P/E

    44.89

  • P/E

    15.03

  • EV/EBITDA

    9.98

  • Debt/Equity (Industry)

    0.17

  • Interest Cover (Industry)

    18.17

  • ROCE (Industry)

    20.59

  • RONW (Industry)

    17.62

  • ROE

    10.64

  • ROCE

    10.06

  • Debt/Equity

    1.48

  • EPS (TTM)

    3.75

  • Dividend Yield

    0

  • Book Value

    69.66

  • Interest Cover

    2.19

Analysis

all

thumbs up icon

Pros

  • Godavari Drugs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Godavari Drugs is profitable, therefore cash runway is not a concern.
  • Godavari Drugs is profitable, therefore cash runway is not a concern.
  • Debt is covered by short term assets, assets are 2.3x debt.
  • Godavari Drugs's cash and other short term assets cover its long term commitments.
thumbs up icon

Cons

  • Unable to evaluate Godavari Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Godavari Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Debt is not well covered by operating cash flow (15.1%, less than 20% of total debt).
  • The level of debt compared to net worth has increased over the past 5 years (31.5% vs 129.5% today).
  • Interest payments on debt are not well covered by earnings (EBIT is 2x annual interest expense, ideally 3x coverage).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters40.2352.6152.6152.6352.63
FII00000
DII2.470.500.500.500.50
Public57.3046.8946.8946.8746.87
Government00000

Read More

Technical Analysis

RSI

40.61

MACD

-4.00

50 DMA

113.76

200 DMA

99.46

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic159.68136.68121.37113.6898.3790.6867.68
Fibonacci136.68127.90122.47113.68104.9099.4790.68
Camarilla112.38110.27108.16113.68103.94101.8399.72

Pivots Level: Classic

R3

+46

159.68

R2

+23

136.68

R1

+7.68

121.37

113.68
113.68
Pivot Point
LTP: 100

S1

-15.32

98.37

S2

-23

90.68

S3

-46

67.68

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    101.37

  • 20-EMA

    104.24

  • 30-EMA

    106.90

  • 50-EMA

    110.02

  • 100-EMA

    109.80

  • 200-EMA

    104.63

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
27 May 2026board-meetingsAccounts, Quarterly Results
21 Jan 2026egm
14 Nov 2025board-meetingsQuarterly Results
04 Aug 2025agm
30 May 2024agm
21 Jul 2023agm
25 Apr 2022agm
23 Jul 2021agm

Read More

Peer Comparison

Godavari Drugs Ltd logo

Godavari Drugs Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

Godavari Drugs Ltd About

Godavari Drugs engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and its intermediates through its manufacturing facility at Nanded, Maharashtra, India.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1987

Headquarters

CEO

Ghanshyam Jaju

Employees

Contact

Website icon

Website

http://www.godavaridrugs.com

Email icon

Email

info@godavaridrugs.com

Phone icon

Phone

91-40-27849700/27844557

Location icon

Location

Mayfair 1-8-303-34, Sardar Patel Road, Secunderabad, Andhra Pradesh, 500003

Read More

Godavari Drugs Ltd Company History

YearHistory
1987
  • GODAVARI DRUGS LIMITED was incorporated as a private limited company on December 2.
1988
  • The company set up a project to manufacture 180 TPA of SULPHAMETHOXAZOLE.
1989
  • The project to manufacture SULPHAMETHOXAZOLE was fully commissioned on July 3.
1992
  • The company was converted into a public limited company on September 25.
2012
  • The Board appointed Mr. Mohit Jaju as an Additional Director effective from May 10.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
TRADELINK EXIM INDIA PVT LTDbulkBuy3921798.8816 Jan 2026
MADHUSUDHAN GUNDAbulkBuy40000106.226 Aug 2024
MADHUSUDHAN GUNDAbulkSell3389211226 Aug 2024
PRASHANT SHRIMALbulkSell4183393.5215 Jun 2023
PRASHANT SHRIMALbulkSell1551678806 Jun 2023
SUSHMA KAKANIbulkBuy700008806 Jun 2023
MOHIT JAJUbulkBuy7000087.9906 Jun 2023
YUGA STOCKS AND COMMODITIES PRIVATE LIMITED .bulkSell4500075.7619 Dec 2022
YUGA STOCKS AND COMMODITIES PRIVATE LIMITED .bulkBuy4500075.7819 Dec 2022
ARHAM SHARE PRIVATE LIMITEDbulkSell4056474.9319 Dec 2022

Read More

Godavari Drugs Ltd News

Godavari Drugs closes trading window for Q1FY27

Godavari Drugs Limited closed its trading window from July 1, 2026, until 48 hours after Q1FY27 results are declared, complying with SEBI regulations.

23 Jun 2026

companies

Godavari Drugs board meets on May 27

Godavari Drugs Limited will hold a board meeting on May 27, 2026, to consider audited financial results for FY26. The trading window closes on April 1.

22 May 2026

companies

Godavari Drugs Submits Q4FY26 SEBI Compliance Certificate

Godavari Drugs Limited submitted its certificate under SEBI Regulation 74(5) for Q4FY26, confirming compliance with dematerialization requirements for the quarter ended March 31, 2026.

08 Apr 2026

companies

Godavari Drugs: Prashant Shrimal Files SEBI Disclosure

Promoter group member Prashant Shrimal filed SEBI disclosure for acquiring 1,12,360 equity shares through preferential allotment, representing 1.11% shareholding and 0.90% diluted shareholding.

23 Mar 2026

companies

Godavari Drugs: Ghanshyam Jaju Acquires 1.8L Warrants

Promoter Ghanshyam Jaju acquired 1,80,000 convertible warrants through preferential allotment, increasing his total holding to 5,30,000 securities representing 4.24% diluted shareholding.

20 Mar 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number